Laboratory Corporation of America Holdings (NYSE:LH) – Research analysts at William Blair dropped their FY2017 earnings per share (EPS) estimates for shares of Laboratory Corporation of America Holdings in a report issued on Tuesday. William Blair analyst A. Murphy now expects that the medical research company will earn $9.53 per share for the year, down from their previous forecast of $9.56. William Blair also issued estimates for Laboratory Corporation of America Holdings’ Q4 2017 earnings at $2.38 EPS, Q1 2018 earnings at $2.39 EPS, Q2 2018 earnings at $2.66 EPS, Q4 2018 earnings at $2.56 EPS and FY2018 earnings at $10.39 EPS.

LH has been the subject of a number of other research reports. Barclays PLC lifted their price objective on shares of Laboratory Corporation of America Holdings from $182.00 to $183.00 and gave the company an “overweight” rating in a report on Thursday, July 27th. Zacks Investment Research raised shares of Laboratory Corporation of America Holdings from a “sell” rating to a “hold” rating in a report on Thursday, July 27th. SunTrust Banks, Inc. reissued a “buy” rating and set a $190.00 target price on shares of Laboratory Corporation of America Holdings in a research note on Thursday, October 12th. Robert W. Baird reissued a “hold” rating and set a $150.00 target price on shares of Laboratory Corporation of America Holdings in a research note on Friday, October 27th. Finally, ValuEngine cut shares of Laboratory Corporation of America Holdings from a “buy” rating to a “hold” rating in a research note on Tuesday, September 26th. Seven research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $169.00.

WARNING: “FY2017 Earnings Estimate for Laboratory Corporation of America Holdings (LH) Issued By William Blair” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/11/24/fy2017-earnings-estimate-for-laboratory-corporation-of-america-holdings-lh-issued-by-william-blair.html.

Laboratory Corporation of America Holdings (NYSE LH) opened at $151.91 on Thursday. Laboratory Corporation of America Holdings has a 1 year low of $123.36 and a 1 year high of $164.22. The company has a current ratio of 1.89, a quick ratio of 1.75 and a debt-to-equity ratio of 1.18. The stock has a market cap of $15,470.00, a price-to-earnings ratio of 16.43, a P/E/G ratio of 1.62 and a beta of 0.87.

Laboratory Corporation of America Holdings (NYSE:LH) last posted its earnings results on Wednesday, October 25th. The medical research company reported $2.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.38 by $0.08. The company had revenue of $2.60 billion during the quarter, compared to the consensus estimate of $2.55 billion. Laboratory Corporation of America Holdings had a net margin of 7.40% and a return on equity of 16.75%. The firm’s quarterly revenue was up 9.5% on a year-over-year basis. During the same period in the previous year, the firm posted $2.25 earnings per share.

A number of large investors have recently bought and sold shares of LH. Aperio Group LLC lifted its holdings in shares of Laboratory Corporation of America Holdings by 23.3% in the 2nd quarter. Aperio Group LLC now owns 51,991 shares of the medical research company’s stock worth $8,014,000 after acquiring an additional 9,813 shares during the last quarter. APG Asset Management N.V. lifted its holdings in shares of Laboratory Corporation of America Holdings by 10.6% in the 2nd quarter. APG Asset Management N.V. now owns 423,427 shares of the medical research company’s stock worth $65,267,000 after acquiring an additional 40,642 shares during the last quarter. Quantitative Systematic Strategies LLC lifted its holdings in shares of Laboratory Corporation of America Holdings by 28.7% in the 2nd quarter. Quantitative Systematic Strategies LLC now owns 6,949 shares of the medical research company’s stock worth $1,058,000 after acquiring an additional 1,550 shares during the last quarter. Regentatlantic Capital LLC lifted its holdings in shares of Laboratory Corporation of America Holdings by 0.5% in the 2nd quarter. Regentatlantic Capital LLC now owns 1,696 shares of the medical research company’s stock worth $261,000 after acquiring an additional 8 shares during the last quarter. Finally, Shell Asset Management Co. lifted its holdings in shares of Laboratory Corporation of America Holdings by 4.1% in the 2nd quarter. Shell Asset Management Co. now owns 12,689 shares of the medical research company’s stock worth $1,956,000 after acquiring an additional 500 shares during the last quarter. Institutional investors own 92.96% of the company’s stock.

In other Laboratory Corporation of America Holdings news, Director Dwight Gary Gilliland sold 971 shares of the business’s stock in a transaction dated Monday, October 30th. The shares were sold at an average price of $153.52, for a total value of $149,067.92. Following the transaction, the director now directly owns 3,501 shares in the company, valued at approximately $537,473.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO David P. King sold 132,713 shares of the business’s stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $157.06, for a total transaction of $20,843,903.78. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 178,371 shares of company stock valued at $28,002,575. 0.90% of the stock is owned by corporate insiders.

Laboratory Corporation of America Holdings Company Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Earnings History and Estimates for Laboratory Corporation of America Holdings (NYSE:LH)

Receive News & Stock Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related stocks with our FREE daily email newsletter.